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ABSTRACT
It has long been acknowledged that the cephalosporin breakpoints used in most European countries and
the USA fail to detect many or most extended spectrum b-lactamases (ESBLs) in Enterobacteriaceae and
that all ESBLs are clinically signiﬁcant. Therefore, microbiological laboratories have undertaken not only
regular cephalosporin susceptibility tests based on breakpoints, but also special tests to detect all ESBLs.
An increasing accumulation of clinical data implies that the clinical success of third generation
cephalosporin therapy is related more to the minimum inhibitory concentration (MIC) than to the
presence or absence of an ESBL. However, the breakpoints must be lower than those previously
recommended by many breakpoint committees. In Europe, this adjustment has been achieved by
EUCAST (European Committee on Antimicrobial Susceptibility Testing) through the ongoing process of
harmonising European breakpoints. In the USA, the CLSI recently voted to adopt similar guidelines but
are waiting to implement these while revising other b-lactam breakpoints. As Enterobacteriaceae are
becoming increasingly resistant, a less ‘diehard’ interpretation of the relationship among MICs, ESBLs
and clinical outcome may provide therapeutic alternatives in difﬁcult situations.
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Both the European Committee on Antimicrobial
Susceptibility Testing (EUCAST) [1] and the Clin-
ical Laboratory Standards Institute (CLSI) [2] in the
USA have recently revised breakpoints for third-
generation cephalosporins. In Europe, this was
part of the ongoing European harmonisation of
clinical breakpoints for all existing antimicrobials
and involves the national breakpoint committees
in Europe, including the CA-SFM [3] in France, the
DIN [4] in Germany, the CRG [5] in The Nether-
lands, the NWGA [6] in Norway, the SRGA [7] in
Sweden, and the BSAC Working Party on Antimi-
crobial Susceptibility Testing [8] in the UK.
EUCAST is organised through the European Soci-
ety for Clinical Microbiology and Infectious Dis-
eases (ESCMID) [9] and is ﬁnanced by ESCMID,
the national breakpoint committees and a 3-year
(2005–2007) grant from DG Sanco of the European
Union with a 1-year extension through the Euro-
pean Centre for Disease Control.
The new European cephalosporin breakpoints
were ﬁnalised on 31 March 2006 (alongside those
for aztreonam and carbapenems). The cephalo-
sporins for intravenous use that were dealt with
were cefuroxime, cefotaxime, ceftriaxone, ceftaz-
idime and cefepime. In the USA, the CLSI
Working Group on Enterobacteriaceae made pre-
sentations to the CLSI, and a vote was called for,
during several meetings (2003–2005). However,
new CLSI breakpoints will not be operative until
CLSI procedures for revising breakpoints, and
their legal implications, have been resolved. The
breakpoints recommended by CLSI and by
national breakpoint committees in Europe prior
to the revision are shown in Table 1.
A major issue in both committees has been
whether new clinical Enterobacteriaceae MIC
breakpoints could predict clinical success and
failure even without ancillary tests or whether
laboratories need to continue to screen for, and
conﬁrm the presence or absence of, extended
spectrum b-lactamases (ESBLs) before issuing a
susceptibility report. Having reviewed the avail-
able data, both EUCAST and the CLSI concluded
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that: (i) there was a need for lowering of many of
the current breakpoints; and (ii) correct clinical
breakpoints could obviate the need for ESBL
screening for the prediction of clinical outcome,
whereas both detection and characterisation
would continue to be of importance for infection
control and surveillance purposes.
BREAKPOINTS NEED REVISION
The history of breakpoints has shown that initial
breakpoints are often overly optimistic. Almost
without exception, revisions have resulted in a
lowering of the initial breakpoint. New resistance
mechanisms need to be assessed, doses and
indications may change, and new drugs within
the class provoke a need for re-evaluation of the
breakpoints of existing drugs. As tools for deter-
mining breakpoints improve, older breakpoints
can be subjected to re-examination using the new
tools.
The proliferation of cephalosporin breakpoints
in Europe highlighted the need for revision and
harmonisation in itself. Some committees felt that
their existing breakpoints did not allow detection
of important resistance mechanisms and did not
correlate well with clinical outcome. Recent stud-
ies and compilations of clinical data suggest that
clinical outcome is better correlated with the MIC
value than with the presence or absence of an
ESBL enzyme [10–13]. Furthermore, the screening
techniques used in addition to, or as a substitute
for, relevant MIC breakpoints need constant
adjustments to keep up with the rapidly increas-
ing number of b-lactamases in a rapidly rising
number of species [14]. Laboratories are currently
required to make sure: (i) that the MIC is equal to
or below (or the equivalent zone diameter is equal
to or above) the breakpoint; and (ii) that the
isolate is devoid of an ESBL. Thus, despite the fact
that the isolate may be characterised as suscepti-
ble according to the breakpoint, the laboratory
needs to exclude the presence of a resistance
mechanism. When a resistance mechanism is
detected (by use of a screening test), the labora-
tory needs to determine whether this is an ESBL,
in which case the isolate should be automatically
reported as resistant to that and other cephalo-
sporins and to penicillins and aztreonam, even
though the efﬁcacy of b-lactamase inhibitors is
debated. If the ESBL test is negative, a different
resistance mechanism (e.g., AmpC, impermeabil-
ity) is assumed, in which case the isolate may be
categorised as susceptible to that cephalosporin.
However, a separate test would be required in
order to report on other cephalosporins. It is not
surprising that the screening for and identiﬁca-
tion of ESBLs often delay the susceptibility report
by one or more days and that many laboratories
ﬁnd it difﬁcult to keep up with changing and
complicated recommendations. The expensive,
time-consuming and no less complicated alterna-













BSAC UK 8 ⁄ 16 1 ⁄ 1 1 ⁄ 1 2 ⁄ 2 1 ⁄ 1
CA-SFM France 8 ⁄ 32 4 ⁄ 32 4 ⁄ 32 4 ⁄ 32 4 ⁄ 32
CLSI USA 8 ⁄ 16 8 ⁄ 32 8 ⁄ 32 8 ⁄ 16 8 ⁄ 16
CRG The Netherlands 4 ⁄ 16 4 ⁄ 16 4 ⁄ 16 4 ⁄ 16 NA
DIN Germany 4 ⁄ 8 2 ⁄ 8 4 ⁄ 16 4 ⁄ 16 4 ⁄ 16
EUCAST Europe – – – – –
NWGA Norway 0.5 ⁄ 8 1 ⁄ 4 1 ⁄ 4 1 ⁄ 8 NA
SRGA Sweden 8 ⁄ 8 0.5 ⁄ 1 0.5 ⁄ 1 2 ⁄ 4 0.5 ⁄ 1
aSee text for abbreviations.
NA, not available.
All breakpoints, including CLSI breakpoints, are expressed as X ⁄Y, interpreted as S £ X, R > Y.
Table 2. Dosages of third-generation cephalosporins rele-
vant for EUCAST revised cephalosporin breakpoints
Daily dosage
Low High Maximum (g)
Cefuroxime 0.75 g · 3 1.5 g · 3 4.5
Cefotaxime 1 g · 3 ‡2 g · 3 12
Ceftriaxone 1 g · 1 ‡2 g · 1 4
Ceftazidime 1 g · 3 2 g · 3 6
Cefepime 1 g · 3 2 g · 3 6
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tive is to subject each isolate to a wide range of
tests upon initial evaluation.
Considering all these points, cephalosporin
breakpoints were subjected to independent revi-
sion by the EUCAST and the CLSI, using modern
tools such as pharmacokinetic and pharmacody-
namic considerations [15], modern dosing (Ta-
ble 2) and the results from several compilations of
clinical outcome data, all indicating that the MIC




The revised cephalosporin breakpoints are listed
in Table 3 and the doses used by EUCAST in
setting the new breakpoints are listed in Table 2.
Neither committee intended for the revised
breakpoints to detect all ESBL-producing isolates
of Enterobacteriaceae. The breakpoints were
determined as clinical breakpoints, i.e., to predict
clinical outcome. However, in the majority of
cases, and in comparison with the majority of the
hitherto recommended breakpoints, the new
breakpoints will allow detection of isolates with
ESBLs [16].
Both committees recommend that, for epidemi-
ological reasons, laboratories should continue to
characterise resistance to third-generation cepha-
losporins. Correct species identiﬁcation, detection
and characterisation of resistance mechanisms
and, above all, the typing of isolates have obvious
roles in infection control and resistance surveil-
lance. In addition, with the rising incidence
of ESBL-producing Enterobacteriaceae in and
outside hospitals, it becomes increasingly impor-
tant to submit all Enterobacteriaceae isolates, not
only those from cases of septicaemia, to cephalo-
sporin susceptibility testing, and to devise alert













CLSIc USA 8a ⁄ 8 1 ⁄ 2 1 ⁄ 2 4 ⁄ 8 8 ⁄ 16
EUCASTd Europe 8a ⁄ 8 1 ⁄ 2 1 ⁄ 2 1 ⁄ 8b 1 ⁄ 8b
EUCAST PK ⁄PDe 4 ⁄ 8 1 ⁄ 2 1 ⁄ 2 4 ⁄ 8 4 ⁄ 8
aThe S breakpoint for cefuroxime was adjusted—the pharmacokinetics and pharmacodynamics suggest a breakpoint of
S £4 mg ⁄L. To avoid dividing the cefuroxime MIC distributions of wild-type Enterobacteriaceae (Fig. 1), both committees
increased the S breakpoint to 8 mg ⁄L and suggested that the higher cefuroxime dosage be used for infections with
Enterobacteriaceae (Table 2).
bThe ceftazidime and cefepime S breakpoints were adjusted from 4 to 1 mg ⁄L to ensure that Enterobacteriaceae with
clinically important extended spectrum b-lactamases (ESBLs) were not reported as susceptible.
cCLSI breakpoints will not be operative until other b-lactam breakpoints have also been revised.
dEUCAST breakpoints (31 March 2006) will be implemented during 2007 by national breakpoint committees in Europe.
eEUCAST pharmacokinetic ⁄pharmacodynamic breakpoints—as part of the EUCAST breakpoint process, EUCAST
determines the theoretical breakpoint for each antimicrobial agent. This is based primarily on the pharmacokinetic and
pharmacodynamic properties of the drug.
All breakpoints were expressed as S £ X ⁄R > Y.






















Cefuroxime 8 8 8 4 8 8–16 16
Cefotaxime 0.25 0.12 0.12 0.06 0.5 0.5 0.5
Ceftriaxone 0.25 0.12 0.12 0.06 NA 0.5 NA
Ceftazidime 0.5 0.5 0.5 0.12 1 1 2
Cefepime 0.12 0.12 0.12 0.12 0.12 0.12 NA
NA, not available.
Isolates with WT MIC values should be devoid of extended spectrum b-lactamases (ESBLs) or other resistance
mechanisms.
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systems that will indicate clonal and polyclonal
outbreaks of ESBL-producing Enterobacteriaceae
in hospitals and the community.
The revised EUCAST cephalosporin break-
points should ensure a clinically meaningful
cephalosporin susceptibility categorisation of En-
Fig. 1. MIC distributions for wild-type Escherichia coli and Klebsiella pneumoniae for cefotaxime (top), ceftazidime (middle)
and cefepime (bottom) from the EUCAST website (http://www.eucast.org), last accessed on 28 December 2006.
Epidemiological cut-off values are shown in the lower left corner and the clinical breakpoints in the lower right corner.
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terobacteriaceae. The frequent delay in reporting
can be eliminated by recommending breakpoints
that provide susceptibility categorisation without
additional tests. If this is not the case, the
breakpoint committees have failed.
In daily practice, the revised breakpoints will
mean that if any of cefotaxime, ceftriaxone,
ceftazidime or cefepime tests ‘R’, and no other
cephalosporin tests were performed, the labora-
tory must report the tested cephalosporin as ‘R’,
with a warning about the probability of other
cephalosporins testing resistant. The same would
apply, in the absence of other information, to a
positive cefpodoxime ESBL screen test but, com-
pared with a combination of cefotaxime and
ceftazidime, this has a substantially higher per-
centage of ‘false-positives’ [17].
The issue that is now generating discussion is
whether an isolate testing ‘S’ for one third-
generation cephalosporin and ‘R’ for another
(e.g., cefotaxime being ‘R’ and ceftazidime ‘S’)
can be reported as tested, with (or even without) a
warning about the possibility of an ESBL. The
studies referred to earlier suggest that this is the
case. Other investigators insist that there is
enough evidence to the contrary. The controversy
is difﬁcult to resolve. To conduct a prospective
clinical study would be difﬁcult, and most avail-
able clinical evidence is anecdotal and ⁄ or gener-
ated with the high breakpoints and ESBL-
screening strategies recommended by the CLSI.
The discussion will go on for some time to come.
The EUCAST epidemiological cut-off values
(Table 4, Fig. 1) offer an alternative to using
cefpodoxime for sensitive screening for (and
quantitation of) ESBLs in Enterobacteriaceae.
Any isolate found to be outside the non-wild-
type for either cefotaxime and ⁄ or ceftazidime
and ⁄ or cefepime (Fig. 1) should be suspected of
producing an ESBL and subjected to further
analysis. Techniques to conﬁrm and characterise
ESBLs and other broad-spectrum b-lactamases are
described elsewhere [18, internal reference].
To perform susceptibility testing and screening
for ESBLs simultaneously, the revised EUCAST
clinical breakpoints, in combination with the
epidemiological cut-off values, can be used. To
test Escherichia coli and Klebsiella pneumoniae (and,
when relevant, Proteus mirabilis, Citrobacter spp.
and Salmonella spp.), cefotaxime (or ceftriaxone)
and ceftazidime should be used. The results, MIC
values and inhibition zone diameters can be
interpreted according to the clinical breakpoint
and the epidemiological cut-off for each drug. The
breakpoint will give the clinical susceptibility
categorisation for the two cephalosporins, and the
epidemiological cut-off will disclose the possible
presence of an ESBL (or other resistance mecha-
nisms). This provides, within 18–20 h, a clinical
susceptibility report and a screen for ESBLs and
other third-generation resistance mechanisms and
allows these isolates to be subjected to further
characterisation of the resistance mechanism.
In summary, an isolate with an MIC value
above (or zone diameter correlate below) the
epidemiological cut-off for that species should be
suspected of having a resistance mechanism,
which may be an ESBL. It is still controversial
whether it is safe to classify isolates with MIC
values below (or zone diameter correlates above)
the revised EUCAST (or CLSI) clinical breakpoint
as susceptible to the drug in question unless a
speciﬁc ESBL-screening test has been performed.
Old habits die hard, and many microbiologists
will hesitate to report an E. coli or K. pneumoniae
isolate as susceptible to a cephalosporin once an
ESBL has been detected, even though studies
show that failures are associated with cefotaxime,
ceftriaxone or ceftazidime MICs of 4 mg ⁄L or
more.[12] Lowering the susceptiblity breakpoints
of cefotaxime, cetriaxone, ceftazidime and cefe-
pime to 1 mg ⁄L should provide a wider margin of
safety for those who wish to report cephalosporin
susceptibilities in Enterobacteriaceae as tested.
For epidemiological reasons, the revised break-
points should be combined with screening tech-
niques to detect ESBLs or other broad-spectrum b-
lactamases [18]. However, susceptibility categor-
isation (S, I and R) must not be delayed by a
desire to conﬁrm and ⁄ or characterise resistance
mechanisms.
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